"For the 2023-2024 formulation of the COVID-19 vaccines for use in the U.S. beginning in the fall of 2023, the committee unanimously voted that the vaccine composition be updated to a monovalent COVID-19 vaccine with an XBB-lineage of the Omicron variant. Following discussion of the evidence, the committee expressed a preference for XBB.1.5."
https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023
--
#FDA #VRBPAC #covid #XBB #vaccine
#fda #vrbpac #covid #xbb #vaccine
Novavax Fall 2023 Vaccine Booster Update
#Novavax presented at the June 15th #FDA #VRBPAC meeting to provide neutralization results from testing with various combinations of the original #vaccine, #BA.5, #XBB.1.5 and #XBB.1.16 #boosters. This thread will highlight the presentation. 🧵 1/
An unrolled one-page web view for this long thread that may be easier to read or share can be found here ( https://twitter.com/jeffgilchrist/status/1678356489449140226 )
#Novavax #fda #vrbpac #vaccine #ba #xbb #boosters
There was lots of concern expressed at today's #VRBPAC meeting about preterm births & concomitant administration of vaccines during pregnancy. But at the end of the day, there was clear support for Pfizer's maternal #RSV vaccine to protect infants. https://www.statnews.com/2023/05/18/fda-advisory-panel-backs-pfizers-rsv-vaccine-but-expresses-some-safety-concerns/
Previously, 🎢🌶🧪27JAN2023 "#Seroprevalence by #Vaccine and/or Natural Infection -gives an idea about current population level immunity . . . . This will play a role in last week's @US_FDA #VRBPAC meeting discussions" (Raj Rajnarayanan @RajlabN Assistant Dean of Research and Associate Professor, NYITCOM) #immunity 🦠 #mRNA #booster #infection #vaccine #breakthrough graphic VRBPAC CONFERENCE #UPDATE
#seroprevalence #vaccine #vrbpac #immunity #mrna #booster #infection #breakthrough #update
🎢🌶🧪 UPDATE 29JAN2023 #VRBPAC "The most recent data on US Covid #seroprevalence demonstrate a large proportion of people age 50+ have vaccine only induced immunity Which bodes against the annual shot durable protection hypothesis" (EricTOPOL, erictopol.com) ** Lack of seroconversion to virus major confounder:** (G_Commish) [fda.gov/media/164814/download] https://t.co/JNgEaC1hfx 35 pg download!!! EricTopol/status/1619030804931440641 #FDA
@fifilamoura #VRBPAC terms of reference are limited to vaccination advice to the FDA. Not sure who’d be the public health equivalent (masks, ventilation) in the USA.
I suspect that here in Canada, over time, it will be WorkSafe and the like that will drive ventilation regulations. Unions could do more for their members to push it as well.
RT @HelenBranswell
In a surprisingly conflict-free #VRBPAC meeting, the committee voted 21-0 to support FDA's plan to move towards a simplified #Covid vaccination program with a single composition for primary series & boosters. https://www.statnews.com/2023/01/26/fda-advisers-recommend-updating-covid-vaccines/
RT @RajlabN@twitter.com
#Seroprevalence by #Vaccine and/or Natural Infection -gives an idea about current population level immunity
This will play a role in today's @US_FDA@twitter.com #VRBPAC meeting discussions
#seroprevalence #vaccine #vrbpac
The future of the US #Covid vaccination policy will be debated today at a meeting of FDA's adcomm, #VRBPAC.
@matthewherper & I will be live blogging the discussions, which promise to be lively. We'll keep you up to date if you check back often here: https://www.statnews.com/2023/01/26/live-blog-tracking-the-meeting-of-the-fda-advisory-panel-on-covid-vaccines/